AstraZeneca, Pfizer Japan and more—FiercePharmaAsia by Angus Liu Friday, February 15, 2019 AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.
Will mutant strains hurt prospects for Roche's Xofluza? by Carly Helfand Monday, February 11, 2019 Roche’s Xofluza has yet to see widespread uptake in the U.S., and new reports of resistance in Japan won’t help the drug’s case.
Pfizer Japan finds impurities in valsartan made with Mylan API by Eric Palmer Friday, February 8, 2019 The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India.
Takeda won't sell OTC unit despite pharma's consumer exodus: CEO by Angus Liu Monday, January 7, 2019 Takeda will probably not sell its OTC business to help pay off the $31 billion loan it’s taking to finance the Shire takeover, its CEO says.
Mallinckrodt spinoff to include 7 manufacturing sites by Eric Palmer Tuesday, December 18, 2018 With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with manufacturing sites in the U.S. and Japan.
Auto czar’s fall is a warning for Takeda's Weber—Editor’s Corner by Angus Liu Tuesday, November 27, 2018 Takeda CEO Christophe Weber and Nissan's now-fallen chairman Carlos Ghosn have much more in common than their French nationality.
Sun gets dermatology portfolio, 2 plants in Japan by Eric Palmer Monday, November 26, 2018 Sun Pharma is picking up two manufacturing plants and a portfolio of dermatology drugs in Japan for just $1 million.
J&J's consumer biz to pay $2.1B for Japan cosmetics firm Ci:z by Angus Liu Tuesday, October 23, 2018 The deal follows a flurry of consumer deals and comes as J&J's beauty products have been delivering strong growth, thanks in part to Ci:z.
FDA hits Japanese API maker with warning letter over lab data by Joseph Keenan Wednesday, August 1, 2018 The FDA slapped Japanese API maker Yuki Gosei Kogyo with a warning letter for failing to report lab testing data on released lots.